Pavel Printsev, Director of Business Development, will provide an up-to-date company overview as well as an introduction to its clinical-stage assets
Oncology: BBT-176 and BBT-207 (Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations)
Pulmonology: BBT-877 (Autotaxin inhibitor for idiopathic pulmonary fibrosis)
Earlier this year, the company announced its acquisition of a diagnostics company with a novel biosensing technology. The company presentation is expected to include an introduction to the newly acquired biosensing technology and commercial prospects.
'We are pleased to share the progress of clinical assets as well as new business activities through an in-person presentation at this year's
(C) 2023 Electronic News Publishing, source